medigraphic.com
SPANISH

Revista Cubana de Reumatología

ISSN 1817-5996 (Electronic)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 3

<< Back Next >>

Rev Cub de Reu 2019; 21 (3)

Gout Arthritis. Ten years of follow up

Vizcaíno LY, Bermúdez MWM, Bermúdez MWA, Egües MJL, Cárdenas DT, Prendes GE
Full text How to cite this article

Language: English
References: 25
Page: 1-14
PDF size: 400.70 Kb.


Key words:

gouty arthritis, gout, uric acid, hyperuricaemia.

ABSTRACT

Introduction: gouty arthritis is a persistent metabolic disease that produces an increase of the circulating uric acid, with the resulting deposit of monosodic urate crystals in the tissues.
Objective: to characterize patients with gouty arthritis clinically and epidemiologically.
Methods: a descriptive investigation of 72 patients with a diagnosis of gouty arthritis, assisted at Arnaldo Milián Castro Clinical Surgical University Hospital was carried out from January 2008 to December 2017.
Results: patients between 40 and 49 years of age were the most representative group with a highest incidence in not white patients and the male sex. Obesity and hypertension prevailed as previous personal antecedents. Alcohol intake was the most represented toxic habit. A crisis of inflammation of the big toe was the more frequent starting manifestation. Swelling of soft tissues was the main radiologic alteration.
Conclusion: gouty arthritis is present with a highest frequency in the male sex with a peak of incidence in the fourth decade of life. It is associated to bad diet habits and alcohol intake that could cause joint damage.


REFERENCES

  1. Singh JA, Yu S. Gout-related inpatient utilization: a study of predictors of outcomes and time trends. Arthritis Res Ther. 2015;18(1):57.

  2. Jeyaruban A, Soden M, Larkins S. General practitioners’ perspectives on the management of gout: a qualitative study. Postgrad Med J. 2016;92(1092):603-7.

  3. Humphrey C, Hulme R, Dalbeth N, Gow P, Arroll B, Lindsay K. A qualitative study to explore health professionals’ experience of treating gout: understanding perceived barriers to effective gout management. J Prim Health Care. 2016;8(2):149-56.

  4. Chandratre P, Mallen CD, Roddy E, Liddle J, Richardson J. “You want to get on with the rest of your life”: a qualitative study of health-related quality of life in gout. Clin Rheumatol. 2016;35(5):1197-205.

  5. Pérez Ruíz F. Gota. En: Sociedad Española de Reumatología. Manual SER de las Enfermedades Reumáticas. 6ta ed. Barcelona: Ed. Elsevier; 2014. p. 489-495.

  6. Arthritis Research. Can Epigenetics Switch Off Gout? [Internet]. 2017 Jun [cited 2017 Sep 5]. Available from: https://curearthritis.org/epigenetics-gout/

  7. Prior JA, Mallen CD, Chandratre P, Muller S, Richardson J, Roddy E. Gout characteristics associate with depression, but not anxiety, in primary care: baseline findings from a prospective cohort study. Joint Bone Spine. 2016;83(5):553-8.

  8. Singh JA. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther. 2014;16(2):R82.

  9. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210-7.

  10. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology. Rheumatology. 2012;46:1372-4.

  11. SchumacherJr HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout J Rheumatol. 2013;32:2452-5.

  12. Singh JA, Bharat A, Khanna D, Aquino-Beaton C, Persselin JE, Duffy E, Elashoff D, Khanna PP. Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology (Oxford). 2017;56(1):103-12.

  13. Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16(3):R132.

  14. Martínez Larrarte JP. Caracterización de los pacientes con gota atendidos en la consulta externa del hospital regional de Malabo. Rev Cubana de Reumatolo. 2010;12(16):[aprox. 8 p.]

  15. Monu J, Pope T. Gout: a clinical and radiological review. Radiol Clin North Am. 2013;42(1).

  16. Pinto J, Mora G, Fernández-Ávila D, Gutiérrez J, Díaz M, Grupo Javeriana de Investigaciones en Enfermedades Reumáticas. Tocilizumab en pacientes con gota tofácea severa en pacientes refractarios a tratamientos. Unidad de Reumatología. Departamento de Medicina Interna. Hospital Universitario San Iguala. Pontificia Universidad Javeriana. Bogotá. Colombia. Reumatol Clin [Internet]. 2013 [citado 5 Sep 2017];9(3):178- 80. Available from: http://www.Reumatologíaclínica.org

  17. Singh JA. Gout and comorbidity: a nominal group study of people with gout. Arthritis Research & Therapy [Internet]. 2017 [cited 2019 Jan 3];19(1):204. Available from: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1416-8

  18. Sicras-Mainar A. Álvarez RV. Galera Llorca J. Granell Villalón M. Navarro-Artieda R. Estudio de pacientes con gota: características clínicas en los últimos 2 años de seguimiento. Gaceta Médica de México. 2012;148:448-56. Available from: http://www.medigraphic.com/pdfs/gaceta/gm-2012/gm125d.pdf

  19. Hospital General de Vancouver Canadá y Harvard Medical School, de Boston EEUU. [Internet]. 2012 [cited 2013 Jan 7]. Available from: http://www.dietas.com/articulos/los-refrescos-azucarados-contribuyen-a-la-gota-segun-estudio.asp

  20. Liddle J, Roddy E, Mallen CD, Hider SL, Prinjha S, Ziebland S, Richardson JC. Mapping patients’ experiences from initial symptoms to gout diagnosis: a qualitative exploration. BMJ Open. 2015;5(9):e008323.

  21. Artritis Foundation. What is gout [Internet]. 2015 [cited 2017 Mar 10]. Available from: https://www.arthritis.org/about-arthritis/types/gout/what-is-gout.php

  22. González-Rozas M. Prieto de Paula JM, Franco Hidalgo S, López Pedreira MR. Gota tofácea crónica. Semergen. 2013;39(6):e29-e34. Available from: www.elsevier.es/semergen

  23. Puig J, Torres R, Mateos F, Ramos T, Arcas J, Buño A, et al. The spectrum of Hypoxantine-guanine phosphoribosyl/transferase (HPRT) deficiency. Clinical experience based on 22 patients from 18 spanish families. Medicine (Baltimore). 2012;84:102-12.

  24. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39–49.

  25. Arthritis Foundation. [Internet]. 2012 [citado 2019 Jan 7]. Available from: http://www.arthritis.org/espanol/er--gota-obesidad.php




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Cub de Reu. 2019;21